{"_id":"hl7.fhir.us.pq-cmc-fda","name":"hl7.fhir.us.pq-cmc-fda","dist-tags":{"latest":"2.0.0"},"versions":{"2.0.0":{"name":"hl7.fhir.us.pq-cmc-fda","_id":"hl7.fhir.us.pq-cmc-fda@5.0.0","version":"2.0.0","date":"2025-07-08T07:43:10.000Z","fhirVersion":"5.0.0","kind":"fhir.ig","count":0,"canonical":"http://hl7.org/fhir/us/pq-cmc-fda","url":"https://packages2.fhir.org/web/hl7.fhir.us.pq-cmc-fda-2.0.0.tgz","dist":{"shasum":"c97ca2490b8dc04cc4087139397da9fa09b02ba6","tarball":"https://packages2.fhir.org/web/hl7.fhir.us.pq-cmc-fda-2.0.0.tgz"},"homepage":"http://hl7.org/fhir/us/pq-cmc-fda/STU2","license":"CC0-1.0","author":{"name":"HL7 International / Biomedical Research and Regulation"},"description":"The FDA PQ-CMC FHIR IG is for submission of structured and standardized information regarding drug product quality, chemistry, manufacturing and processes controls.  This data is intended for submission to the US FDA by biopharmaceutical companies for the purpose of drug application review. (built Tue, Jul 8, 2025 07:43+0000+00:00)","dependencies":{"hl7.fhir.uv.extensions.r5":"5.2.0","hl7.terminology.r5":"6.4.0"}},"2.0.0-ballot":{"name":"hl7.fhir.us.pq-cmc-fda","_id":"hl7.fhir.us.pq-cmc-fda@5.0.0","version":"2.0.0-ballot","date":"2024-12-12T12:00:00.000Z","fhirVersion":"5.0.0","kind":"fhir.ig","count":0,"canonical":"http://hl7.org/fhir/us/pq-cmc-fda","url":"https://packages2.fhir.org/web/hl7.fhir.us.pq-cmc-fda-2.0.0-ballot.tgz","dist":{"shasum":"3db15371963f932e3741b647b934b5cbb40c4441","tarball":"https://packages2.fhir.org/web/hl7.fhir.us.pq-cmc-fda-2.0.0-ballot.tgz"},"homepage":"http://hl7.org/fhir/us/pq-cmc-fda/2025Jan","license":"CC0-1.0","author":{"name":"HL7 International / Biomedical Research and Regulation"},"description":"The FDA PQ-CMC FHIR IG is for submission of structured and standardized information regarding drug product quality, chemistry, manufacturing and processes controls.  This data is intended for submission to the US FDA by biopharmaceutical companies for the purpose of drug application review. (built Thu, Dec 12, 2024 18:53+0000+00:00)","dependencies":{"hl7.terminology.r5":"6.1.0","hl7.fhir.uv.extensions.r5":"5.1.0"}},"1.0.0":{"name":"hl7.fhir.us.pq-cmc-fda","_id":"hl7.fhir.us.pq-cmc-fda@5.0.0","version":"1.0.0","date":"2024-12-11T12:00:00.000Z","fhirVersion":"5.0.0","kind":"fhir.ig","count":0,"canonical":"http://hl7.org/fhir/us/pq-cmc-fda","url":"https://packages2.fhir.org/web/hl7.fhir.us.pq-cmc-fda-1.0.0.tgz","dist":{"shasum":"99a56c6ec8eff457b5688ba450177313e576b81b","tarball":"https://packages2.fhir.org/web/hl7.fhir.us.pq-cmc-fda-1.0.0.tgz"},"homepage":"http://hl7.org/fhir/us/pq-cmc-fda/STU1","license":"CC0-1.0","author":{"name":"HL7 International / Biomedical Research and Regulation"},"description":"The FDA PQ-CMC FHIR IG is for submission of structured and standardized information regarding drug product quality, chemistry, manufacturing and processes controls.  This data is intended for submission to the US FDA by biopharmaceutical companies for the purpose of drug application review. (built Wed, Dec 11, 2024 13:39+0000+00:00)","dependencies":{"hl7.fhir.uv.extensions.r5":"5.1.0","hl7.terminology.r5":"6.1.0"}},"1.0.0-ballot":{"name":"hl7.fhir.us.pq-cmc-fda","_id":"hl7.fhir.us.pq-cmc-fda@5.0.0","version":"1.0.0-ballot","date":"2024-04-08T12:00:00.000Z","fhirVersion":"5.0.0","kind":"fhir.ig","count":0,"canonical":"http://hl7.org/fhir/us/pq-cmc-fda","url":"https://packages2.fhir.org/web/hl7.fhir.us.pq-cmc-fda-1.0.0-ballot.tgz","dist":{"shasum":"39d4d1b4ee52fb68d0dc7c0de09b7a453acc2e83","tarball":"https://packages2.fhir.org/web/hl7.fhir.us.pq-cmc-fda-1.0.0-ballot.tgz"},"homepage":"http://hl7.org/fhir/us/pq-cmc-fda/2024May","license":"CC0-1.0","author":{"name":"HL7 International / Biomedical Research and Regulation"},"description":"The FDA PQ-CMC FHIR IG  is for submission of structured and standardized information regarding drug product quality, chemistry, manufacturing and processes controls.  This data is intended for submission to the US FDA by biopharmaceutical companies for the purpose of drug application review. (built Mon, Apr 8, 2024 17:45+0000+00:00)","dependencies":{"hl7.terminology":"5.5.0","hl7.fhir.uv.extensions.r5":"1.0.0"}}},"description":"The FDA PQ-CMC FHIR IG  is for submission of structured and standardized information regarding drug product quality, chemistry, manufacturing and processes controls.  This data is intended for submission to the US FDA by biopharmaceutical companies for the purpose of drug application review. (built Mon, Apr 8, 2024 17:45+0000+00:00)"}